Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Ligumsky, H
Do NOT double dose: More is not better
To protect its intellectual property, the API manufacturer files its proprietary CMC information in a DMF
Overall, the benefits of GLP-1 agonists in terms of weight loss and improved metabolic health generally outweigh the potential risks, particularly when used under the guidance of a healthcare professional
Side Effects Comparison# Retatrutide Side Effects# Phase 2 data (n=338 obesity trial): Nausea : ~25% at higher doses (8-12 mg) Diarrhea : ~20% Vomiting : ~15% Constipation : Common Decreased appetite : Common (pharmacological effect) Heart rate : Small increase (2-4 bpm), potentially related to glucagon component Injection site reactions : Mild, transient Discontinuation rate : 6-10% due to adverse events The glucagon receptor component introduces theoretical concerns for hyperglycemia (counterbalanced by GLP-1/GIP in practice), cardiovascular effects (chronotropic glucagon action), and hepatic effects, none of which produced safety signals in Phase 2 but require larger-scale monitoring
US$ 21.98
US$ 28.51
US$ 23.86
US$ 27.09
US$ 25.13
